|
Studies of treatment with interferon-α for prevention of HCC in patients with hepatitis B-related cirrhosis |
|||||||
| Author [reference] |
Country |
Type of study |
Interferon regimen (duration in weeks) |
Follow-up (range) in months |
Sample size |
Rate of HCC (n/n) |
Significance |
|
|
|||||||
| Oon, 1992 [183] |
Singapore |
NRCT, P |
10 MU daily, 10 days/month (12) |
12 (12–60) |
T 600 C 180 |
T: 0/600 (0%) C: 10/180 (5.6%) |
Significant |
| Mazzella, 1996 [184] |
Italy |
NRCT, P |
10 MU tiw (26) |
49 (12–119) |
T 34 C 28 |
T: 2/34 (5.9%) C: 4/28 (14.3%) |
Not significant |
| Fattovich, 1997 [185] |
Europe |
NRCT, P |
≥ 300 MU (12–52) |
84 (80–92) |
T 40 C 50 |
T: 3/40 (7.5%) C: 4/50 (8.0%) |
Not significant |
| Ikeda, 1998 [186] |
Japan |
NRCT, P |
12 MU/wk (26) |
84 (6–168) |
T 94 C 219 |
T: 10/94 (10.6%) C: 51/219 (23.3%) |
Significant |
| IHCSG, 1998 [187] |
Argentina, Germany, Italy, Saudi Arabia |
NRCT, P |
9–30 MU/wk for 3–30 months |
(36–250) |
T 49 C 97 |
T: 8/49 (16.3%) C: 18/97 (18.6%) |
Not significant |
| Benvegnù, 1998 [188] |
Italy |
NRCT, P |
6–10 MU (20–26) |
72 |
T 10 C 18 |
T: 0/10 (0%) C: 4/18 (22.2%) |
Not significant |
| Di Marco, 1999 [189] |
Italy |
NRCT, P |
655 MU |
93 (6–180) |
T 26 C 60 |
T: 2/26 (7.7%) C: 6/60 (10%) |
NR |
|
NRCT: non-randomized controlled trial P: prospective T: treated C: controls MU: million units NR: not reported | |||||||
Michielsen et al. World Journal of Surgical Oncology 2005 3:27 doi:10.1186/1477-7819-3-27 |
|||||||